<DOC>
	<DOC>NCT02391805</DOC>
	<brief_summary>This randomized, multicenter, partially double-blind, placebo-controlled study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antiviral effects of treatment with RO6864018 in virologically suppressed participants with chronic HBV infection.</brief_summary>
	<brief_title>A Study of Treatment With RO6864018 in Virologically Suppressed Participants With Chronic Hepatitis B Virus (HBV) Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Adults 18 to 65 years of age Chronic hepatitis B infection Positive test for HBsAg for more than 6 months prior to randomization HBsAg titer greater than or equal to (&gt;/=) 250 international units per milliliter (IU/mL) at Screening Treatment with any nucleoside/nucleotide analogue for &gt;/= 1 year with ongoing entecavir or tenofovir treatment at randomization and for at least 3 months prior to randomization HBV DNA less than (&lt;) 90 IU/mL for at least the preceding 6 months HBeAg positive at randomization and for at least 6 months prior to randomization Pregnant or lactating women Documented history of HBV genotype D History or other evidence of bleeding from esophageal varices History of decompensated liver disease, chronic liver disease other than HBV infection, or any evidence of metabolic liver disease Positive test for hepatitis A, hepatitis C, or human immunodeficiency virus (HIV) Documented history of hepatitis D infection History of or suspicion of hepatocellular carcinoma History of immunologically mediated disease History of organ transplantation History of thyroid disease Significant acute infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>